Xuehua Chen – Trademark Portfolio
Entity Type: 01
Xuehua Chen has 5 U.S. trademark filings recorded with the United States Patent and Trademark Office (USPTO). Of these, 2 are successfully registered — a 67% registration rate, with 2 applications currently pending. The portfolio includes marks such as ASIVUD and CYNFELVIRIX. Filings span 4 Nice Classification classes, with the highest activity in Class 5 (Pharmaceuticals) and Class 9 (Computers & Electronics). This trademark owner is based in Jinjiang,Fujian.
No. 146, Cangjiang Middle District
Guocen Village, Dongshi Town
Jinjiang,Fujian 362200 , CN
Showing of trademarks Trademarks
Trademark Classifications
Xuehua Chen's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Paper and cardboard; printed matter; bookbinding material; photographs; stationery
Frequently Asked Questions
How many trademarks does Xuehua Chen have?
Xuehua Chen has 5 U.S. trademarks filed with the USPTO. Of these, 2 registered, 2 pending, 1 abandoned.
What trademark classes does Xuehua Chen file in?
Xuehua Chen files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 24 (Fabrics), Class 16 (Paper Goods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Xuehua Chen's most well-known trademarks?
Xuehua Chen's registered trademark portfolio includes well-known marks such as ASIVUD and CYNFELVIRIX. These are among 2 currently registered trademarks in the portfolio.
What is Xuehua Chen's trademark registration success rate?
Xuehua Chen has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 2 applications are pending review.